Business Context and Reporting Period
This Form 8-K is a current report filed by Oric Pharmaceuticals, Inc. on July 28, 2026. The filing addresses corporate governance and equity incentive matters rather than periodic financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the amendment of an equity incentive plan.
Material Changes
- Equity Plan Amendment: The Board of Directors approved the "Amended and Restated 2022 Inducement Equity Incentive Plan."
- Share Reserve Increase: An additional 1,100,000 shares of common stock were reserved for issuance, bringing the aggregate total reserved under the plan to 3,350,000 shares.
- Regulatory Compliance: The amendment was adopted without stockholder approval pursuant to applicable Nasdaq Listing Rules.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. The primary commentary relates to the terms of the Inducement Plan:
- Eligibility: Awards are restricted to individuals not previously employed by the Company (or those with a bona fide period of non-employment) as an inducement material to their entry into employment.
- Acquisition Exception: Awards may also be made in connection with a merger or acquisition as permitted by Nasdaq rules.
- Award Types: The plan covers nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares, and performance stock units.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 3,350,000 shares reserved under the Inducement Plan.
- Review Exhibit 10.1 (Amended and Restated 2022 Inducement Equity Incentive Plan) for specific vesting schedules and performance metrics.
- Confirm the Company's current cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K does not disclose liquidity status.
- Monitor future filings for actual grants made under this plan to identify new key hires or acquisition-related compensation.